Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Barnett

Showing results (391-400 of 409) with videos related to

Pageof 41
Sort By:
The Journal of Infectious Diseases|September 20, 2014
Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsionWilly M Bogers, Herman Oostermeijer, Petra Mooij, et al.
AIDS Research and Human Retroviruses|August 4, 2015
IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine RegimensNicos Karasavvas, Chitraporn Karnasuta, Hathairat Savadsuk, et al.
Frontiers in Immunology|August 8, 2022
Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 StudyBeatriz Perdiguero, Benedikt Asbach, Carmen E Gómez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2020
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope ProteinMina C Hosseinipour, Craig Innes, Sarita Naidoo, et al.
Blood Advances|January 4, 2018
Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPsJoseph R Francica, Daniel E Zak, Caitlyn Linde, et al.
Journal of Virology|February 10, 2017
HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman PrimatesJuan García-Arriaza, Beatriz Perdiguero, Jonathan L Heeney, et al.
Journal of Virology|June 5, 2015
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman PrimatesJuan García-Arriaza, Beatriz Perdiguero, Jonathan Heeney, et al.
Plos Pathogens|April 29, 2020
Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and typeLuca Schifanella, Susan W Barnett, Massimiliano Bissa, et al.
Plos Pathogens|December 4, 2019
ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and typeLuca Schifanella, Susan W Barnett, Massimiliano Bissa, et al.
Nature Communications|April 11, 2015
Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunizationJoseph R Francica, Zizhang Sheng, Zhenhai Zhang, et al.
Pageof 41

Showing results (391-400 of 409) with videos related to

Sort By:
Pageof 41
The Journal of Infectious Diseases|September 20, 2014
Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsionWilly M Bogers, Herman Oostermeijer, Petra Mooij, et al.
AIDS Research and Human Retroviruses|August 4, 2015
IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine RegimensNicos Karasavvas, Chitraporn Karnasuta, Hathairat Savadsuk, et al.
Frontiers in Immunology|August 8, 2022
Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 StudyBeatriz Perdiguero, Benedikt Asbach, Carmen E Gómez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2020
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope ProteinMina C Hosseinipour, Craig Innes, Sarita Naidoo, et al.
Blood Advances|January 4, 2018
Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPsJoseph R Francica, Daniel E Zak, Caitlyn Linde, et al.
Journal of Virology|February 10, 2017
HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman PrimatesJuan García-Arriaza, Beatriz Perdiguero, Jonathan L Heeney, et al.
Journal of Virology|June 5, 2015
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman PrimatesJuan García-Arriaza, Beatriz Perdiguero, Jonathan Heeney, et al.
Plos Pathogens|April 29, 2020
Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and typeLuca Schifanella, Susan W Barnett, Massimiliano Bissa, et al.
Plos Pathogens|December 4, 2019
ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and typeLuca Schifanella, Susan W Barnett, Massimiliano Bissa, et al.
Nature Communications|April 11, 2015
Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunizationJoseph R Francica, Zizhang Sheng, Zhenhai Zhang, et al.
Pageof 41